Arena sold the globalcommercialization rights to the weight-loss drug, Belviq, to Japanese drugmaker Eisai Co Ltd early last year.
2
Biogen will be responsible for the globalcommercialization of lixivaptan and Cardiokine will have an option for limited co-promotion in the United States.